LON:DPH

Dechra Pharmaceuticals (DPH) Share Forecast, Price & News

GBX 3,798

-6.00 (-0.16%)

(As of 04:45 PM ET)

Compare

Today's Range: 3,794
▼
3,808
50-Day Range: 3,688
▼
3,816
52-Week Range: 2,473.32
▼
4,145.84

Volume: 580,615 shs
Average Volume: 920,223 shs
Market Capitalization: £4.33 billion

P/E Ratio: 10,550.00
Dividend Yield: 1.18%
Price Target: GBX 3,606.40

Profile Analyst Ratings Chart Competitors Dividend Insider Trades Headlines

Dechra Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.80 Rating Score
Upside/Downside: 5.0% Downside
GBX 3,606.40 Price Target
Short Interest: N/A
Dividend Strength: Weak
Based on Four Factors
Sustainability: N/A
News Sentiment: 0.22
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.13 out of 5 stars

1.4

Analyst's Opinion

Consensus Rating
Dechra Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of GBX 3,606.40, Dechra Pharmaceuticals has a forecasted downside of 5.0% from its current price of GBX 3,798.
Amount of Analyst Coverage
Dechra Pharmaceuticals has received no research coverage in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for DPH.

0.8

Dividend Strength

Dividend Yield
Dechra Pharmaceuticals pays a meaningful dividend of 1.19%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
Dechra Pharmaceuticals does not have a long track record of dividend growth.
Dividend Coverage
The dividend payout ratio of Dechra Pharmaceuticals is 12,500.00%. Payout ratios above 75% are not desirable because they may not be sustainable.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for DPH.

2.3

News and Social Media Coverage

News Sentiment
Dechra Pharmaceuticals has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Dechra Pharmaceuticals this week, compared to 1 article on an average week.
MarketBeat Follows
1 people have added Dechra Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Dechra Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.43% of the stock of Dechra Pharmaceuticals is held by insiders.
Percentage Held by Institutions
85.98% of the stock of Dechra Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Dechra Pharmaceuticals is 10,550.00, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 118.64.
Price to Earnings Ratio vs. Sector
The P/E ratio of Dechra Pharmaceuticals is 10,550.00, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 118.70.
Price to Earnings Growth Ratio
Dechra Pharmaceuticals has a PEG Ratio of 1.42. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Dechra Pharmaceuticals has a P/B Ratio of 5.10. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Dechra Pharmaceuticals (LON:DPH) Stock

Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, and critical care products for dogs and cats; water soluble antibiotics, poultry vaccines, and pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies. It also provides pet nutrition products for supporting cats and dogs with various therapeutic conditions, such as allergies, obesity, heart, and kidney diseases. In addition, the company distributes veterinary pharmaceuticals and equipment; offers financial services; markets pet diets; and develops, regulates, manufactures, and markets crop protection. It markets its products through wholesaler and distributor networks. The company operates in the United Kingdom, Germany, rest of Europe, the United States, and internationally. Dechra Pharmaceuticals PLC was incorporated in 1997 and is headquartered in Northwich, the United Kingdom.

DPH Price History

30 days | 90 days | 365 days | Advanced Chart

DPH Stock News Headlines

September 21, 2023 | marketwatch.com

Dechra Pharmaceuticals falls Thursday, still outperforms market

September 21, 2023 | americanbankingnews.com

Dechra Pharmaceuticals (LON:DPH) Share Price Crosses Above 200-Day Moving Average of $3,470.27

September 25, 2023 | Behind the Markets (Ad)

Laser breakthrough could send stock soaring 2,467%

Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...

September 20, 2023 | finance.yahoo.com

Form 8.3 - Dechra Pharmaceuticals plc - Amendment

September 15, 2023 | finance.yahoo.com

Form 8.3 - DPH LN Equity 14-September-23 Dealing Disclosure

August 31, 2023 | markets.businessinsider.com

Back in the Big League: M&S Rejoins the FTSE 100 on Share Price Boost

August 22, 2023 | finance.yahoo.com

Marks & Spencer Set for FTSE 100 Comeback After This Year’s 78% Share Price Rise

August 15, 2023 | marketwatch.com

Dechra Pharmaceuticals remains steady Tuesday, still outperforms market

September 25, 2023 | Behind the Markets (Ad)

Laser breakthrough could send stock soaring 2,467%

July 20, 2023 | bloomberg.com

DPH: Carlson Capital, L.P.: Form 8.3 - Dechra Pharmaceuticals plc

July 12, 2023 | finance.yahoo.com

Form 8.3 - DPH LN Equity 11-July-23 Increase in Traded Position

July 6, 2023 | marketwatch.com

Dechra Pharmaceuticals remains steady Thursday, still outperforms market

July 6, 2023 | finance.yahoo.com

DCHPF - Dechra Pharmaceuticals PLC

July 5, 2023 | marketwatch.com

Dechra Pharmaceuticals outperforms market despite losses on the day

July 3, 2023 | finance.yahoo.com

Form 8.3 - DPH LN Equity 30-June-23 Increase in Traded Position

June 28, 2023 | finance.yahoo.com

Form 8.3 - DPH LN Equity 27-June-23 Dealing Disclosure

June 6, 2023 | finance.yahoo.com

Form 8.3 - Dechra Pharmaceuticals PLC [DPH LN]

June 6, 2023 | finance.yahoo.com

Form 8.3 - Dechra Pharmaceuticals

June 5, 2023 | finance.yahoo.com

Form 8.3 - DPH LN

June 3, 2023 | reuters.com

EQT ups bet on pet industry with $5.6 bln Dechra deal

June 2, 2023 | msn.com

The Dechra share price holds a lesson for all investors!

May 28, 2023 | msn.com

Deutsche Reiterates Dechra Pharmaceuticals (LSE:DPH) Outperform Recommendation

May 26, 2023 | finance.yahoo.com

Form 8.3 - DECHRA PHARMA

May 24, 2023 | msn.com

European stocks muted as U.S. debt ceiling concerns linger

May 23, 2023 | msn.com

UK's Dechra slumps after profit warning

May 22, 2023 | reuters.com

UK's Dechra down after profit warning

May 18, 2023 | lse.co.uk

Medicine and Biotech Sector Regulatory News

See More Headlines

Receive DPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dechra Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: LON
Industry: Drug Manufacturers—General
Sub-Industry: N/A
Sector: Medical
Current Symbol: LON:DPH
CUSIP: N/A
CIK: N/A
Web: www.dechra.com
Phone: +44-1606-814730
Fax: N/A
Employees: 1,998
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: GBX 3,606.40
High Stock Price Forecast: GBX 4,070
Low Stock Price Forecast: GBX 2,850
Forecasted Upside/Downside: -5.0%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.80
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): GBX 0.36
Trailing P/E Ratio: 10,550.00
Forward P/E Ratio: 20.38
P/E Growth: 1.42
Net Income: £40.10 million
Net Margins: 5.52%
Pretax Margin: N/A
Return on Equity: 5.42%
Return on Assets: 3.65%

Debt

Debt-to-Equity Ratio: 60.73
Current Ratio: 2.73
Quick Ratio: 1.66

Sales & Book Value

Annual Sales: £726.80 million
Price / Sales: 5.95
Cash Flow: GBX 155.46 per share
Price / Cash Flow: 24.43
Book Value: GBX 744 per share
Price / Book: 5.10

Miscellaneous

Outstanding Shares: 113,890,000
Free Float: N/A
Market Cap: £4.33 billion
Optionable: Not Optionable
Beta: 0.79

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Mr. Ian D. Page (Age 62)
CEO, MD & Exec. Director
Comp: $1.26M

Mr. Paul Nicholas Sandland MAAT (Age 44)
FCCA, CFO & Exec. Director
Comp: $790k

Dr. Anthony Gerard Griffin (Age 60)
MD of Dechra Veterinary Products for Europe & Exec. Director
Comp: $601k

Mr. Patrick Meeus
Group Scientific Officer

Mr. Jamie Adams
Chief Information Officer

Ms. Katy Clough
Group HR Director

Mr. Mike Eldred (Age 53)
Pres of North America

Ms. Melanie Jane Hall
Company Sec.

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

DPH Stock - Frequently Asked Questions

Should I buy or sell Dechra Pharmaceuticals stock right now?: 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Dechra Pharmaceuticals in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" DPH shares.
View DPH analyst ratings or view top-rated stocks.
What is Dechra Pharmaceuticals' stock price forecast for 2023?: 5 analysts have issued 12 month price targets for Dechra Pharmaceuticals' shares. Their DPH share price forecasts range from GBX 2,850 to GBX 4,070. On average, they anticipate the company's share price to reach GBX 3,606.40 in the next year. This suggests that the stock has a possible downside of 5.0%.
View analysts price targets for DPH or view top-rated stocks among Wall Street analysts.
How have DPH shares performed in 2023?: Dechra Pharmaceuticals' stock was trading at GBX 2,618 at the beginning of 2023. Since then, DPH shares have increased by 45.1% and is now trading at GBX 3,798.
View the best growth stocks for 2023 here.
How often does Dechra Pharmaceuticals pay dividends? What is the dividend yield for Dechra Pharmaceuticals?: Dechra Pharmaceuticals declared a dividend on Monday, February 27th. Investors of record on Thursday, March 9th will be paid a dividend of GBX 12.50 per share on Thursday, April 13th. This represents a dividend yield of 0.4%. The ex-dividend date of this dividend is Thursday, March 9th. The official announcement can be seen at this link.
Read our dividend analysis for DPH.
Is Dechra Pharmaceuticals a good dividend stock?: Dechra Pharmaceuticals (LON:DPH) pays an annual dividend of GBX 45 per share and currently has a dividend yield of 1.19%. The dividend payout ratio is 12,500.00%. Payout ratios above 75% are not desirable because they may not be sustainable.
Read our dividend analysis for DPH.
What other stocks do shareholders of Dechra Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Dechra Pharmaceuticals investors own include 32Red (TTR), 1428686 (SGP.L) (SGP), JD Sports Fashion (JD), Ashtead Group (AHT), Cranswick (CWK), Drax Group (DRX), RPC Group (RPC), Robert Walters (RWA), SEB (SKP) and Barratt Developments (BDEV).

What is Dechra Pharmaceuticals' stock symbol?: Dechra Pharmaceuticals trades on the London Stock Exchange (LON) under the ticker symbol "DPH."
How do I buy shares of Dechra Pharmaceuticals?: Shares of DPH stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.
What is Dechra Pharmaceuticals' stock price today?: One share of DPH stock can currently be purchased for approximately GBX 3,798.
How much money does Dechra Pharmaceuticals make?: Dechra Pharmaceuticals (LON:DPH) has a market capitalization of £4.33 billion and generates £726.80 million in revenue each year. The company earns £40.10 million in net income (profit) each year or GBX 0.36 on an earnings per share basis.
How many employees does Dechra Pharmaceuticals have?: The company employs 1,998 workers across the globe.
How can I contact Dechra Pharmaceuticals?: Dechra Pharmaceuticals' mailing address is 24 Cheshire Business Park Cheshire Avenue, NORTHWICH, CW9 7UA, United Kingdom. The official website for the company is www.dechra.com. The company can be reached via phone at +44-1606-814730.

This page (LON:DPH) was last updated on 9/25/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Dechra Pharmaceuticals (DPH) Share Forecast, Price & News

Dechra Pharmaceuticals MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Dechra Pharmaceuticals (LON:DPH) Stock

DPH Price History

DPH Stock News Headlines

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders

DPH Stock - Frequently Asked Questions

Overall MarketRank^™